Danimer Scientific Faces Compliance Challenge, Secures New Financing
Bainbridge, Ga. ’ Danimer Scientific, Inc. (NYSE: DNMR), a prominent bioplastics firm known for its innovative biodegradable materials, has recently encountered a notable compliance issue and secured a significant financial backing to support its operations.NYSE Compliance Notice
Danimer Scientific announced on May 21, 2024, that it had received a continued listing standard notice from the New York Stock Exchange (NYSE). The notice indicates that the company is currently not in compliance with a key NYSE listing requirement. Specifically, the company’s stock has failed to maintain an average closing price of at least $1.00 per share over a certain period.
Financing Boost from Mountain Ridge Capital
In a strategic move to bolster its financial stability, Danimer Scientific disclosed that it entered into an asset-based revolving credit and security agreement with Mountain Ridge Capital on April 19, 2024. This agreement primarily utilizes the company’s accounts receivable and inventory as collateral. The facility is valued at $20 million, offering Danimer Scientific the liquidity needed to navigate its ongoing operational challenges.
Previous Compliance Issues
This is not the first time Danimer Scientific has faced compliance issues. The company had previously received an identical notice from the NYSE on January 23, 2024, once again due to the stock not meeting the minimum average closing price standard of $1.00 per share.
Moving Forward
Danimer Scientific’s recent establishment of the revolving credit line is a clear sign of its proactive approach to financial management amidst the compliance challenges. The funds obtained from Mountain Ridge Capital should provide the company with the necessary operational flexibility to continue its advancements in bioplastic technology while addressing the NYSE compliance requirements.
As of now, stakeholders and market watchers will be keenly observing how Danimer Scientific navigates this critical juncture, particularly focusing on the company’s ability to elevate its stock price to meet NYSE listing standards and ensuring long-term financial health and operational success.
’
Comments